These differently enriched ovarian cancer driver mutations demonstrated that Chr3(q26.2) Amp was enriched in HGSCs harboring TP53 mutations and MYC Amp; however, non-HGSCs driven by PIK3CA, PTEN, or KRAS mutations were less likely to carry Chr3(q26.2) Amp. This evidence concerns the gene TP53 and ovarian cancer.